NCT02982486 2017-11-01
A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma
Assaf-Harofeh Medical Center
Phase 2 Unknown
Assaf-Harofeh Medical Center
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)